Blood Cancer Talks Episode 18. Management of Smoldering Multiple Myeloma
1. How I Approach Smoldering Myeloma (Vaxman and Gertz):
https://ashpublications.org/blood/article/140/8/828/485274
2. Risk-Stratification Models in SMM:
Mayo 2018 model: https://pubmed.ncbi.nlm.nih.gov/29895887/
PETHEMA (Spanish) model: https://pubmed.ncbi.nlm.nih.gov/17576818/
PANGEA model: https://pubmed.ncbi.nlm.nih.gov/36858677/
IMWG SMM model: https://pubmed.ncbi.nlm.nih.gov/33067414/
3. QuiRedex RCT (Lenalidomide-Dexamethasone vs Observation in High-Risk SMM):
https://pubmed.ncbi.nlm.nih.gov/36067617/
4. ECOG E3A06 RCT (Lenalidomide vs Observation in SMM):
https://pubmed.ncbi.nlm.nih.gov/31652094/
5. Intensive Treatment in High-Risk Smoldering Multiple Myeloma:
GEM-CESAR: https://ashpublications.org/blood/article/140/Supplement%201/292/490268
ASCENT: https://ashpublications.org/blood/article/140/Supplement%201/1830/492739
6. Current Clinical Trial Landscape in Smoldering Myeloma:
https://pubmed.ncbi.nlm.nih.gov/34114943/
7. How Light Chain Proteinuria Modulates Risk of Progression in Patients with sFLC ratio>100 as the only Myeloma-Defining Event?